Edgar Filing: Loxo Oncology, Inc. - Form 4

Loxo Oncology, Form 4	Inc.										
January 14, 2015									PPROVAL		
FORM 4	UNITED	STATES					COMMISSIO				
Check this box Washington, D.C. 20549						Number:	3235-0287 January 31,				
if no longer subject to Section 16. Form 4 or Form 5	if no longer subject to Section 16.STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESForm 4 or Form 5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934.						Estimated burden hou response	2005 average Irs per			
obligations may continue. <i>See</i> Instruction 1(b).		· · ·		•	U	npany Act ny Act of 1	of 1935 or Secti 940	on			
(Print or Type Respon	nses)										
1. Name and Address of Reporting Person <u>*</u> Fuhrman Alan			2. Issuer Name and Ticker or Trading Symbol Loxo Oncology, Inc. [LOXO]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)		of Earliest T	-	noj	(Che	k all applicable)			
C/O LOXO ONO INC., ONE LAN SUITE 1122	COLOGY,			Day/Year)			X Director Officer (giv below)		6 Owner er (specify		
(STAMFORD, C	(Street) T 06901			endment, D onth/Day/Yea	-	1	6. Individual or Applicable Line) _X_ Form filed by Form filed by Person		erson		
(City) ((State)	(Zip)	Tah	de I - Non-l	Derivative	Securities A	cquired, Disposed	of. or Beneficia	llv Owned		
	ansaction Date hth/Day/Year)	Execution any	ed Date, if	3.	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)			7. Nature of Indirect		
Reminder: Report on	a separate lind	e for each cl	ass of sec	urities bene	Perso inforn requir	ns who rest nation cont ed to response a current	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible :	Beneficially Owner securities)	d			
1. Title of 2.	3. Trans	saction Date	-		4.	5. Number		sable and	7. Title and Amount of		

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Underlying Securities

Expiration Date

Edgar Filing: Loxo Oncology, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	 A) A o (1) (1) 	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		S (1
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Director Stock Option (right to buy)	\$ 11.35	01/12/2015		А	1	15,625		<u>(1)</u>	01/11/2025	Common Stock	15,625	

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Othe				
Fuhrman Alan C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD, CT 06901		Х						
Signatures								
/s/ Alan Fuhrman	01/14/2015							
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests and becomes exercisable as to 1/3 of the shares subject to the option on the one-year anniversary of the grant date, and thereafter vests as to an additional 1/3 of the shares annually.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.